3021 POSTER Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE)

A.Grothey; M.Sugrue; E.Hedrick; D.Purdie; P.Chiruvolu; W.Dong; D.Sargent; M.Kozloff

首页> 外文期刊>European Journal of Cancer Supplements >3021 POSTER Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE)

【24h】

3021 POSTER Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE)

机译：3021 POSTER转移性结直肠癌（mCRC）患者超出首次进展（BBP）的贝伐单抗（BV）暴露与总体生存率（OS）之间的关联：一项大型观察性研究（BRiTE）的结果

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2007年第4期|共2页
作者
A.Grothey; M.Sugrue; E.Hedrick; D.Purdie; P.Chiruvolu; W.Dong; D.Sargent; M.Kozloff;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 3045 POSTER Serious arterial thromboembolic events (sATE) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV): results from the BRiTE registry [J] . A.Sing, M.Sugrue, P.Chiruvolu, European Journal of Cancer Supplements . 2007,第4期

机译：3045海报贝伐单抗（BV）治疗的转移性结直肠癌（mCRC）患者（pts）的严重动脉血栓栓塞事件（sATE）：来自BRiTE注册表的结果
2. 3049 POSTER Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV) plus chemotherapy (CT) [J] . M.Kozloff, J.Hainsworth, S.Badarinath, European Journal of Cancer Supplements . 2007,第4期

机译：3049用贝伐单抗（BV）联合化疗（CT）治疗的转移性结直肠癌（mCRC）患者（pts）的高血压管理（HTN）
3. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). [J] . Grothey A, Sugrue MM, Purdie DM, Journal of Clinical Oncology . 2008,第33期

机译：贝伐珠单抗超过最初的进展与转移性结直肠癌的总体生存期延长有关：一项大型观察性队列研究（BRiTE）的结果。
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. A Modeling-Based Evaluation of the Evidential Basis for and Cost Effectiveness of Intensive Post-Diagnosis Extra-Colonic Surveillance of Non-Metastatic Colorectal Cancer Patients [D] . Popp, Jonah. 2018

机译：非转移性结直肠癌患者强化诊断后大肠结肠镜检查的证据基础和成本效益的基于模型的评估
6. Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine Oxaliplatin Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer [O] . Jan Pander, Lieke van Huis-Tanja, Stefan Böhringer, -1

机译：全基因组关联研究预测转移性结直肠癌一线治疗中卡培他滨奥沙利铂贝伐单抗和西妥昔单抗患者的无进展生存期
7. Survival analysis of a multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC) [O] . A. Avallone, G. Nasti, G. Rosati, 2018

机译：多期一组的生存分析，随机阶段3研究转移结直肠癌患者Fevacizumab与Fevacizumab与Folfox / Oxxel组合的研究（MCRC）

3021 POSTER Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE)

著录项

相似文献

相关主题

期刊订阅